AGIO:NSD-Agios Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 45.66

Change

+0.30 (+0.66)%

Market Cap

USD 3.14B

Volume

0.48M

Average Target Price

USD 68.25 (+49.47%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.60 (+0.74%)

USD56.30B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+2.21 (+0.44%)

USD54.00B 20.76 16.02
MRNA Moderna, Inc

+10.62 (+10.78%)

USD39.00B N/A N/A
SGEN Seagen Inc

+0.82 (+0.50%)

USD29.47B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

-0.18 (-0.15%)

USD26.94B 28.36 26.40
RPRX Royalty Pharma plc

+1.39 (+3.51%)

USD24.75B 23.05 9.48
BNTX BioNTech SE

+3.09 (+3.03%)

USD24.53B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.98 (+3.11%)

USD23.81B N/A N/A
GMAB Genmab A/S

+0.68 (+1.93%)

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AGIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.38% 47% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.38% 47% F 41% F
Trailing 12 Months  
Capital Gain 16.90% 51% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.90% 51% F 63% D
Trailing 5 Years  
Capital Gain -33.87% 51% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.87% 51% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 3.35% N/A N/A 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.35% N/A N/A 43% F
Risk Return Profile  
Volatility (Standard Deviation) 37.68% N/A N/A 35% F
Risk Adjusted Return 8.90% N/A N/A 38% F
Market Capitalization 3.14B 88% B+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.28 31% F 21% F
Price / Cash Flow Ratio -8.48 59% F 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -71.51% 46% F 16% F
Return on Invested Capital -64.20% 48% F 15% F
Return on Assets -25.64% 53% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.94 40% F 24% F
Short Percent 12.46% 25% F 18% F
Beta 1.84 32% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector